# Safety, Tolerability, Distribution & Dose Effect of Neoadjuvant Transarterial Chemoembolization With Doxorubicin in Prostate Cancer Patients Before Radical Prostatectomy

> **NCT04423913** · PHASE2 · TERMINATED · sponsor: **Centre Hospitalier Universitaire de Nīmes** · enrollment: 12 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **OTHER:** Administration of embolization beads

## Key facts

- **NCT ID:** NCT04423913
- **Lead sponsor:** Centre Hospitalier Universitaire de Nīmes
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-04
- **Primary completion:** 2022-06-01
- **Final completion:** 2022-10-31
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Recruitment difficulties
- **Last updated:** 2023-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04423913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04423913, "Safety, Tolerability, Distribution & Dose Effect of Neoadjuvant Transarterial Chemoembolization With Doxorubicin in Prostate Cancer Patients Before Radical Prostatectomy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04423913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*